{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T06:09:49Z","timestamp":1768889389029,"version":"3.49.0"},"reference-count":136,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrinology and Metabolism Clinics of North America"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.ecl.2025.03.017","type":"journal-article","created":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T07:33:35Z","timestamp":1745393615000},"page":"497-519","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Update on Somatic Genomic Alterations in Follicular Cell-Derived Thyroid Cancers"],"prefix":"10.1016","volume":"54","author":[{"given":"William R.","family":"Perry","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas J.","family":"Giordano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.ecl.2025.03.017_bib1","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/jnci\/95.8.625","article-title":"BRAF mutation in papillary thyroid carcinoma","volume":"95","author":"Cohen","year":"2003","journal-title":"J Natl Cancer Inst"},{"issue":"44","key":"10.1016\/j.ecl.2025.03.017_bib2","doi-asserted-by":"crossref","first-page":"7436","DOI":"10.1038\/sj.onc.1207980","article-title":"Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer","volume":"23","author":"Frattini","year":"2004","journal-title":"Oncogene"},{"issue":"29","key":"10.1016\/j.ecl.2025.03.017_bib3","doi-asserted-by":"crossref","first-page":"4578","DOI":"10.1038\/sj.onc.1206706","article-title":"BRAF mutations and RET\/PTC rearrangements are alternative events in the etiopathogenesis of PTC","volume":"22","author":"Soares","year":"2003","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.ecl.2025.03.017_bib4","first-page":"687","article-title":"Prevalence of mutations of ras and p53 in benign and malignant thyroid tumors from children exposed to radiation after the Chernobyl nuclear accident","volume":"13","author":"Nikiforov","year":"1996","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.ecl.2025.03.017_bib5","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1309\/ND8D9LAJTRCTG6QD","article-title":"Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of ras mutations","volume":"120","author":"Zhu","year":"2003","journal-title":"Am J Clin Pathol"},{"issue":"10","key":"10.1016\/j.ecl.2025.03.017_bib6","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1210\/mend-4-10-1474","article-title":"Point mutations of ras oncogenes are an early event in thyroid tumorigenesis","volume":"4","author":"Namba","year":"1990","journal-title":"Mol Endocrinol"},{"issue":"7","key":"10.1016\/j.ecl.2025.03.017_bib7","first-page":"1454","article-title":"High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET\/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma","volume":"63","author":"Kimura","year":"2003","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.ecl.2025.03.017_bib8","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.cell.2014.09.050","article-title":"Integrated genomic characterization of papillary thyroid carcinoma","volume":"159","author":"Cancer Genome Atlas Research","year":"2014","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.ecl.2025.03.017_bib9","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1038\/s41379-018-0070-2","article-title":"Cribriform-morular variant of thyroid carcinoma: a neoplasm with distinctive phenotype associated with the activation of the WNT\/beta-catenin pathway","volume":"31","author":"Cameselle-Teijeiro","year":"2018","journal-title":"Mod Pathol"},{"issue":"10","key":"10.1016\/j.ecl.2025.03.017_bib10","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/s41568-020-0290-x","article-title":"A compendium of mutational cancer driver genes","volume":"20","author":"Martinez-Jimenez","year":"2020","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"10.1016\/j.ecl.2025.03.017_bib11","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.ccell.2018.03.007","article-title":"Genomic and functional approaches to understanding cancer aneuploidy","volume":"33","author":"Taylor","year":"2018","journal-title":"Cancer Cell"},{"issue":"7964","key":"10.1016\/j.ecl.2025.03.017_bib12","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/s41586-023-06054-z","article-title":"Pan-cancer whole-genome comparison of primary and metastatic solid tumours","volume":"618","author":"Martinez-Jimenez","year":"2023","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.ecl.2025.03.017_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2003.12.004","article-title":"Low prevalence of BRAF mutations in radiation-induced thyroid tumors in contrast to sporadic papillary carcinomas","volume":"209","author":"Nikiforova","year":"2004","journal-title":"Cancer Lett"},{"issue":"9","key":"10.1016\/j.ecl.2025.03.017_bib14","doi-asserted-by":"crossref","first-page":"4267","DOI":"10.1210\/jc.2003-032224","article-title":"BRAF mutations are not a major event in post-Chernobyl childhood thyroid carcinomas","volume":"89","author":"Lima","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"10.1016\/j.ecl.2025.03.017_bib15","doi-asserted-by":"crossref","first-page":"4280","DOI":"10.1210\/jc.2004-0172","article-title":"Low frequency of BRAFT1796A mutations in childhood thyroid carcinomas","volume":"89","author":"Kumagai","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.ecl.2025.03.017_bib16","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1089\/thy.2005.15.320","article-title":"BRAF mutations are uncommon in papillary thyroid cancer of young patients","volume":"15","author":"Penko","year":"2005","journal-title":"Thyroid"},{"issue":"1","key":"10.1016\/j.ecl.2025.03.017_bib17","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s11154-023-09840-2","article-title":"Genetic alterations landscape in paediatric thyroid tumours and\/or differentiated thyroid cancer: systematic review","volume":"25","author":"de Sousa","year":"2024","journal-title":"Rev Endocr Metab Disord"},{"issue":"24","key":"10.1016\/j.ecl.2025.03.017_bib18","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1038\/s41388-018-0171-x","article-title":"Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations","volume":"37","author":"Dankner","year":"2018","journal-title":"Oncogene"},{"issue":"8","key":"10.1016\/j.ecl.2025.03.017_bib19","doi-asserted-by":"crossref","first-page":"E1530","DOI":"10.1210\/jc.2013-4389","article-title":"High-sensitivity BRAF mutation analysis: BRAF V600E is acquired early during tumor development but is heterogeneously distributed in a subset of papillary thyroid carcinomas","volume":"99","author":"de Biase","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.ecl.2025.03.017_bib20","doi-asserted-by":"crossref","first-page":"E276","DOI":"10.1210\/jc.2013-2503","article-title":"The increase in thyroid cancer incidence during the last four decades is accompanied by a high frequency of BRAF mutations and a sharp increase in RAS mutations","volume":"99","author":"Jung","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.ecl.2025.03.017_bib21","doi-asserted-by":"crossref","first-page":"4935","DOI":"10.1172\/JCI69766","article-title":"Identification of kinase fusion oncogenes in post-Chernobyl radiation-induced thyroid cancers","volume":"123","author":"Ricarte-Filho","year":"2013","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.ecl.2025.03.017_bib22","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1172\/JCI23237","article-title":"Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer","volume":"115","author":"Ciampi","year":"2005","journal-title":"J Clin Invest"},{"issue":"4","key":"10.1016\/j.ecl.2025.03.017_bib23","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1093\/jnci\/djx209","article-title":"Investigation of the relationship between radiation dose and gene mutations and fusions in post-chernobyl thyroid cancer","volume":"110","author":"Efanov","year":"2018","journal-title":"J Natl Cancer Inst"},{"issue":"6543","key":"10.1016\/j.ecl.2025.03.017_bib24","doi-asserted-by":"crossref","DOI":"10.1126\/science.abg2538","article-title":"Radiation-related genomic profile of papillary thyroid carcinoma after the Chernobyl accident","volume":"372","author":"Morton","year":"2021","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.ecl.2025.03.017_bib25","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1001\/jamaoncol.2022.1655","article-title":"Evaluation of the molecular landscape of pediatric thyroid nodules and use of a multigene genomic classifier in children","volume":"8","author":"Gallant","year":"2022","journal-title":"JAMA Oncol"},{"issue":"13","key":"10.1016\/j.ecl.2025.03.017_bib26","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1002\/cncr.29044","article-title":"The RET oncogene in papillary thyroid carcinoma","volume":"121","author":"Prescott","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.ecl.2025.03.017_bib27","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.cancergen.2018.11.002","article-title":"Novel rearrangements involving the RET gene in papillary thyroid carcinoma","volume":"230","author":"Staubitz","year":"2019","journal-title":"Cancer Genet"},{"key":"10.1016\/j.ecl.2025.03.017_bib28","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.cancergen.2019.07.002","article-title":"ANKRD26-RET - a novel gene fusion involving RET in papillary thyroid carcinoma","volume":"238","author":"Staubitz","year":"2019","journal-title":"Cancer Genet"},{"issue":"2","key":"10.1016\/j.ecl.2025.03.017_bib29","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1677\/ERC-07-0039","article-title":"HOOK3-RET: a novel type of RET\/PTC rearrangement in papillary thyroid carcinoma","volume":"14","author":"Ciampi","year":"2007","journal-title":"Endocr Relat Cancer"},{"issue":"6","key":"10.1016\/j.ecl.2025.03.017_bib30","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1089\/thy.2016.0673","article-title":"Identification of three novel fusion oncogenes, SQSTM1\/NTRK3, AFAP1L2\/RET, and PPFIBP2\/RET, in thyroid cancers of young patients in fukushima","volume":"27","author":"Iyama","year":"2017","journal-title":"Thyroid"},{"issue":"4","key":"10.1016\/j.ecl.2025.03.017_bib31","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/0092-8674(90)90659-3","article-title":"PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas","volume":"60","author":"Grieco","year":"1990","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.ecl.2025.03.017_bib32","first-page":"509","article-title":"Molecular characterization of RET\/PTC3; a novel rearranged version of the RETproto-oncogene in a human thyroid papillary carcinoma","volume":"9","author":"Santoro","year":"1994","journal-title":"Oncogene"},{"issue":"11","key":"10.1016\/j.ecl.2025.03.017_bib33","doi-asserted-by":"crossref","first-page":"5399","DOI":"10.1210\/jc.2003-030838","article-title":"BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas","volume":"88","author":"Nikiforova","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"15","key":"10.1016\/j.ecl.2025.03.017_bib34","first-page":"4561","article-title":"High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines","volume":"63","author":"Xu","year":"2003","journal-title":"Cancer Res"},{"issue":"11","key":"10.1016\/j.ecl.2025.03.017_bib35","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1210\/clinem\/dgab286","article-title":"BRAF V600E status sharply differentiates lymph node metastasis-associated mortality risk in papillary thyroid cancer","volume":"106","author":"Tao","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.ecl.2025.03.017_bib36","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/(SICI)1097-0215(19990105)80:1<32::AID-IJC7>3.0.CO;2-L","article-title":"Distinct frequency of ret rearrangements in papillary thyroid carcinomas of children and adults from Belarus","volume":"80","author":"Smida","year":"1999","journal-title":"Int J Cancer"},{"issue":"3","key":"10.1016\/j.ecl.2025.03.017_bib37","first-page":"1093","article-title":"Pattern of radiation-induced RET and NTRK1 rearrangements in 191 post-chernobyl papillary thyroid carcinomas: biological, phenotypic, and clinical implications","volume":"6","author":"Rabes","year":"2000","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.ecl.2025.03.017_bib38","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/01.pas.0000176432.73455.1b","article-title":"Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas","volume":"30","author":"Adeniran","year":"2006","journal-title":"Am J Surg Pathol"},{"issue":"10","key":"10.1016\/j.ecl.2025.03.017_bib39","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1038\/modpathol.2015.92","article-title":"BRAF V600E and risk stratification of thyroid microcarcinoma: a multicenter pathological and clinical study","volume":"28","author":"Tallini","year":"2015","journal-title":"Mod Pathol"},{"issue":"9","key":"10.1016\/j.ecl.2025.03.017_bib40","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1038\/modpathol.2010.112","article-title":"Molecular genotyping of papillary thyroid carcinoma follicular variant according to its histological subtypes (encapsulated vs infiltrative) reveals distinct BRAF and RAS mutation patterns","volume":"23","author":"Rivera","year":"2010","journal-title":"Mod Pathol"},{"issue":"11","key":"10.1016\/j.ecl.2025.03.017_bib41","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1089\/thy.2018.0198","article-title":"Comprehensive transcriptomic and genomic profiling of subtypes of follicular variant of papillary thyroid carcinoma","volume":"28","author":"Song","year":"2018","journal-title":"Thyroid"},{"issue":"2","key":"10.1016\/j.ecl.2025.03.017_bib42","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1007\/s12253-019-00639-8","article-title":"Molecular profile and clinicopathologic features of follicular variant papillary thyroid carcinoma","volume":"26","author":"Sohn","year":"2020","journal-title":"Pathol Oncol Res"},{"issue":"11","key":"10.1016\/j.ecl.2025.03.017_bib43","first-page":"4232","article-title":"High prevalence of RET\/PTC rearrangements in Ukrainian and Belarussian post-Chernobyl thyroid papillary carcinomas: a strong correlation between RET\/PTC3 and the solid-follicular variant","volume":"84","author":"Thomas","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"issue":"23","key":"10.1016\/j.ecl.2025.03.017_bib44","first-page":"5523","article-title":"The RET\/PTC3 oncogene: metastatic solid-type papillary carcinomas in murine thyroids","volume":"58","author":"Powell","year":"1998","journal-title":"Cancer Res"},{"issue":"7","key":"10.1016\/j.ecl.2025.03.017_bib45","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1210\/er.2007-0007","article-title":"BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications","volume":"28","author":"Xing","year":"2007","journal-title":"Endocr Rev"},{"issue":"10","key":"10.1016\/j.ecl.2025.03.017_bib46","doi-asserted-by":"crossref","DOI":"10.1177\/1010428317713913","article-title":"Role of molecular markers to predict distant metastasis in papillary thyroid carcinoma: promising value of TERT promoter mutations and insignificant role of BRAF mutations-a meta-analysis","volume":"39","author":"Vuong","year":"2017","journal-title":"Tumour Biol"},{"issue":"5","key":"10.1016\/j.ecl.2025.03.017_bib47","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1089\/thy.2016.0350","article-title":"Effects of coexistent BRAF(V600E) and TERT promoter mutations on poor clinical outcomes in papillary thyroid cancer: a meta-analysis","volume":"27","author":"Moon","year":"2017","journal-title":"Thyroid"},{"issue":"12","key":"10.1016\/j.ecl.2025.03.017_bib48","doi-asserted-by":"crossref","first-page":"4390","DOI":"10.1210\/jc.2012-1775","article-title":"The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study","volume":"97","author":"Elisei","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.ecl.2025.03.017_bib49","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/s10238-024-01320-4","article-title":"Genetic alterations and allele frequency of BRAF V600E and TERT mutation in papillary thyroid carcinoma with intermediate-to-high recurrence risk: a retrospective study","volume":"24","author":"Huang","year":"2024","journal-title":"Clin Exp Med"},{"issue":"2","key":"10.1016\/j.ecl.2025.03.017_bib50","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1007\/s00268-011-1383-1","article-title":"BRAF V600E mutation is associated with tumor aggressiveness in papillary thyroid cancer","volume":"36","author":"Kim","year":"2012","journal-title":"World J Surg"},{"issue":"2","key":"10.1016\/j.ecl.2025.03.017_bib51","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1001\/jamaoncol.2016.3288","article-title":"Mortality risk stratification by combining BRAF V600E and TERT promoter mutations in papillary thyroid cancer: genetic duet of BRAF and TERT promoter mutations in thyroid cancer mortality","volume":"3","author":"Liu","year":"2017","journal-title":"JAMA Oncol"},{"issue":"9","key":"10.1016\/j.ecl.2025.03.017_bib52","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1002\/cncr.29934","article-title":"Prognostic effects of TERT promoter mutations are enhanced by coexistence with BRAF or RAS mutations and strengthen the risk prediction by the ATA or TNM staging system in differentiated thyroid cancer patients","volume":"122","author":"Song","year":"2016","journal-title":"Cancer"},{"issue":"25","key":"10.1016\/j.ecl.2025.03.017_bib53","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1200\/JCO.2014.55.5094","article-title":"BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence","volume":"32","author":"Xing","year":"2014","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ecl.2025.03.017_bib54","doi-asserted-by":"crossref","first-page":"R143","DOI":"10.1530\/ERC-15-0533","article-title":"TERT promoter mutations in thyroid cancer","volume":"23","author":"Liu","year":"2016","journal-title":"Endocr Relat Cancer"},{"issue":"12","key":"10.1016\/j.ecl.2025.03.017_bib55","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1002\/cncr.25061","article-title":"Genetic alterations in the RAS\/RAF\/mitogen-activated protein kinase and phosphatidylinositol 3-kinase\/Akt signaling pathways in the follicular variant of papillary thyroid carcinoma","volume":"116","author":"Santarpia","year":"2010","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.ecl.2025.03.017_bib56","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrc969","article-title":"Targeting RAS signalling pathways in cancer therapy","volume":"3","author":"Downward","year":"2003","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"10.1016\/j.ecl.2025.03.017_bib57","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1210\/jc.2002-021907","article-title":"RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma","volume":"88","author":"Nikiforova","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.ecl.2025.03.017_bib58","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1210\/jc.2002-021186","article-title":"Specific pattern of RAS oncogene mutations in follicular thyroid tumors","volume":"88","author":"Vasko","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.ecl.2025.03.017_bib59","doi-asserted-by":"crossref","first-page":"e1006239","DOI":"10.1371\/journal.pgen.1006239","article-title":"Comprehensive analysis of the transcriptional and mutational landscape of follicular and papillary thyroid cancers","volume":"12","author":"Yoo","year":"2016","journal-title":"PLoS Genet"},{"issue":"7","key":"10.1016\/j.ecl.2025.03.017_bib60","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1210\/jc.2018-00277","article-title":"Comprehensive genetic analysis of follicular thyroid carcinoma predicts prognosis independent of histology","volume":"103","author":"Nicolson","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.ecl.2025.03.017_bib61","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1089\/thy.2016.0348","article-title":"RAS mutations, and RET\/PTC and PAX8\/PPAR-gamma chromosomal rearrangements are also prevalent in benign thyroid lesions: implications thereof and A systematic review","volume":"27","author":"Najafian","year":"2017","journal-title":"Thyroid"},{"issue":"2","key":"10.1016\/j.ecl.2025.03.017_bib62","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/his.12150","article-title":"Diagnostic and prognostic implications of the PAX8-PPARgamma translocation in thyroid carcinomas-a TMA-based study of 226 cases","volume":"63","author":"Boos","year":"2013","journal-title":"Histopathology"},{"issue":"1","key":"10.1016\/j.ecl.2025.03.017_bib63","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.cancergencyto.2009.08.001","article-title":"Fluorescence in situ hybridization analysis using PAX8- and PPARG-specific probes reveals the presence of PAX8-PPARG translocation and 3p25 aneusomy in follicular thyroid neoplasms","volume":"196","author":"Chia","year":"2010","journal-title":"Cancer Genet Cytogenet"},{"issue":"38","key":"10.1016\/j.ecl.2025.03.017_bib64","doi-asserted-by":"crossref","first-page":"40418","DOI":"10.18632\/oncotarget.6340","article-title":"Genomic binding and regulation of gene expression by the thyroid carcinoma-associated PAX8-PPARG fusion protein","volume":"6","author":"Zhang","year":"2015","journal-title":"Oncotarget"},{"issue":"10","key":"10.1016\/j.ecl.2025.03.017_bib65","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/nrendo.2014.115","article-title":"Pax-8-PPAR-gamma fusion protein in thyroid carcinoma","volume":"10","author":"Raman","year":"2014","journal-title":"Nat Rev Endocrinol"},{"issue":"17","key":"10.1016\/j.ecl.2025.03.017_bib66","doi-asserted-by":"crossref","first-page":"7156","DOI":"10.1158\/0008-5472.CAN-08-1085","article-title":"CREB3L2-PPARgamma fusion mutation identifies a thyroid signaling pathway regulated by intramembrane proteolysis","volume":"68","author":"Lui","year":"2008","journal-title":"Cancer Res"},{"issue":"8","key":"10.1016\/j.ecl.2025.03.017_bib67","doi-asserted-by":"crossref","first-page":"3106","DOI":"10.1210\/jc.2008-0273","article-title":"Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase\/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers","volume":"93","author":"Liu","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.ecl.2025.03.017_bib68","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1158\/1078-0432.CCR-06-1125","article-title":"Genetic alterations and their relationship in the phosphatidylinositol 3-kinase\/Akt pathway in thyroid cancer","volume":"13","author":"Hou","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.ecl.2025.03.017_bib69","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1097\/PAS.0b013e31822fbc7d","article-title":"Immunohistochemical staining of thyroidectomy specimens for PTEN can aid in the identification of patients with Cowden syndrome","volume":"35","author":"Barletta","year":"2011","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"10.1016\/j.ecl.2025.03.017_bib70","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1089\/thy.2010.0226","article-title":"Thyroid pathology in PTEN-hamartoma tumor syndrome: characteristic findings of a distinct entity","volume":"21","author":"Laury","year":"2011","journal-title":"Thyroid"},{"issue":"1","key":"10.1016\/j.ecl.2025.03.017_bib71","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s12022-020-09661-y","article-title":"Inherited follicular epithelial-derived thyroid carcinomas: from molecular biology to histological correlates","volume":"32","author":"Cameselle-Teijeiro","year":"2021","journal-title":"Endocr Pathol"},{"issue":"4","key":"10.1016\/j.ecl.2025.03.017_bib72","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1530\/ERC-16-0043","article-title":"Prevalence and phenotypic correlations of EIF1AX mutations in thyroid nodules","volume":"23","author":"Karunamurthy","year":"2016","journal-title":"Endocr Relat Cancer"},{"issue":"2","key":"10.1016\/j.ecl.2025.03.017_bib73","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1158\/2159-8290.CD-18-0606","article-title":"EIF1AX and RAS mutations cooperate to drive thyroid tumorigenesis through ATF4 and c-MYC","volume":"9","author":"Krishnamoorthy","year":"2019","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.ecl.2025.03.017_bib74","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.path.2022.09.010","article-title":"On the chopping block: overview of DICER1 mutations in endocrine and neuroendocrine neoplasms","volume":"16","author":"Juhlin","year":"2023","journal-title":"Surg Pathol Clin"},{"issue":"2","key":"10.1016\/j.ecl.2025.03.017_bib75","doi-asserted-by":"crossref","first-page":"347","DOI":"10.3390\/cancers16020347","article-title":"Expanding our knowledge of DICER1 gene alterations and their role in thyroid diseases","volume":"16","author":"Riascos","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.ecl.2025.03.017_bib76","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1210\/clinem\/dgab025","article-title":"Prevalence and spectrum of DICER1 mutations in adult-onset thyroid nodules with indeterminate cytology","volume":"106","author":"Chong","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ecl.2025.03.017_bib77","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1267499","article-title":"Genomic and transcriptomic analyses of thyroid cancers identify DICER1 somatic mutations in adult follicular-patterned RAS-like tumors","volume":"14","author":"Minna","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.ecl.2025.03.017_bib78","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1083382","article-title":"DICER1 RNase IIIb domain mutations trigger widespread miRNA dysregulation and MAPK activation in pediatric thyroid cancer","volume":"14","author":"Ricarte-Filho","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"10.1016\/j.ecl.2025.03.017_bib79","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1007\/s12022-021-09688-9","article-title":"High prevalence of DICER1 mutations and low frequency of gene fusions in pediatric follicular-patterned tumors of the thyroid","volume":"32","author":"Bae","year":"2021","journal-title":"Endocr Pathol"},{"issue":"6","key":"10.1016\/j.ecl.2025.03.017_bib80","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1515\/jpem-2021-0741","article-title":"Genomic landscape of sporadic pediatric differentiated thyroid cancers: a systematic review and meta-analysis","volume":"35","author":"Satapathy","year":"2022","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.ecl.2025.03.017_bib81","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s00428-021-03212-4","article-title":"Expanding the spectrum of thyroid carcinoma with somatic DICER1 mutation: a survey of 829 thyroid carcinomas using MSK-IMPACT next-generation sequencing platform","volume":"480","author":"Ghossein","year":"2022","journal-title":"Virchows Arch"},{"issue":"10","key":"10.1016\/j.ecl.2025.03.017_bib82","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/nrc3802","article-title":"DICER1: mutations, microRNAs and mechanisms","volume":"14","author":"Foulkes","year":"2014","journal-title":"Nat Rev Cancer"},{"issue":"10","key":"10.1016\/j.ecl.2025.03.017_bib83","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1002\/cncr.27893","article-title":"RET\/PTC and PAX8\/PPARgamma chromosomal rearrangements in post-Chernobyl thyroid cancer and their association with iodine-131 radiation dose and other characteristics","volume":"119","author":"Leeman-Neill","year":"2013","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.ecl.2025.03.017_bib84","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1097\/00000478-200208000-00006","article-title":"PAX8-PPARgamma rearrangement in thyroid tumors: RT-PCR and immunohistochemical analyses","volume":"26","author":"Nikiforova","year":"2002","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"10.1016\/j.ecl.2025.03.017_bib85","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1172\/JCI85271","article-title":"Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers","volume":"126","author":"Landa","year":"2016","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.ecl.2025.03.017_bib86","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s40463-022-00594-6","article-title":"EIF1AX mutation in thyroid tumors: a retrospective analysis of cytology, histopathology and co-mutation profiles","volume":"51","author":"Elsherbini","year":"2022","journal-title":"J Otolaryngol Head Neck Surg"},{"issue":"6","key":"10.1016\/j.ecl.2025.03.017_bib87","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.cancergen.2011.05.001","article-title":"On the prevalence of the PAX8-PPARG fusion resulting from the chromosomal translocation t(2;3)(q13;p25) in adenomas of the thyroid","volume":"204","author":"Klemke","year":"2011","journal-title":"Cancer Genet"},{"issue":"8","key":"10.1016\/j.ecl.2025.03.017_bib88","first-page":"3947","article-title":"Expression of PAX8-PPAR gamma 1 rearrangements in both follicular thyroid carcinomas and adenomas","volume":"87","author":"Marques","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"10.1016\/j.ecl.2025.03.017_bib89","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1073\/pnas.1614265114","article-title":"THADA fusion is a mechanism of IGF2BP3 activation and IGF1R signaling in thyroid cancer","volume":"114","author":"Panebianco","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"10.1016\/j.ecl.2025.03.017_bib90","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1089\/thy.2020.0589","article-title":"Clinicopathologic characteristics of thyroid nodules positive for the THADA-IGF2BP3 fusion on preoperative molecular analysis","volume":"31","author":"Morariu","year":"2021","journal-title":"Thyroid"},{"issue":"12","key":"10.1016\/j.ecl.2025.03.017_bib91","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/cncy.21474","article-title":"Thyroid nodules with KRAS mutations are different from nodules with NRAS and HRAS mutations with regard to cytopathologic and histopathologic outcome characteristics","volume":"122","author":"Radkay","year":"2014","journal-title":"Cancer Cytopathol"},{"issue":"7","key":"10.1016\/j.ecl.2025.03.017_bib92","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1089\/thy.2011.0261","article-title":"The associations between RAS mutations and clinical characteristics in follicular thyroid tumors: new insights from a single center and a large patient cohort","volume":"22","author":"Fukahori","year":"2012","journal-title":"Thyroid"},{"issue":"8","key":"10.1016\/j.ecl.2025.03.017_bib93","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1089\/thy.2014.0053","article-title":"NRAS codon 61 mutation is associated with distant metastasis in patients with follicular thyroid carcinoma","volume":"24","author":"Jang","year":"2014","journal-title":"Thyroid"},{"issue":"6","key":"10.1016\/j.ecl.2025.03.017_bib94","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1530\/EJE-17-0456","article-title":"Changes in the clinicopathological characteristics and genetic alterations of follicular thyroid cancer","volume":"177","author":"Song","year":"2017","journal-title":"Eur J Endocrinol"},{"issue":"19","key":"10.1016\/j.ecl.2025.03.017_bib95","doi-asserted-by":"crossref","first-page":"5970","DOI":"10.1158\/1078-0432.CCR-17-1183","article-title":"Genomic alterations in fatal forms of non-anaplastic thyroid cancer: identification of MED12 and RBM10 as novel thyroid cancer genes associated with tumor virulence","volume":"23","author":"Ibrahimpasic","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.ecl.2025.03.017_bib96","doi-asserted-by":"crossref","first-page":"E754","DOI":"10.1210\/jc.2013-3734","article-title":"TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas","volume":"99","author":"Melo","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.ecl.2025.03.017_bib97","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1507\/endocrj.EJ13-0437","article-title":"Follicular thyroid carcinoma with distant metastasis: outcome and prognostic factor","volume":"61","author":"Sugino","year":"2014","journal-title":"Endocr J"},{"issue":"1","key":"10.1016\/j.ecl.2025.03.017_bib98","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s12022-022-09707-3","article-title":"Overview of the 2022 WHO classification of thyroid neoplasms","volume":"33","author":"Baloch","year":"2022","journal-title":"Endocr Pathol"},{"issue":"2","key":"10.1016\/j.ecl.2025.03.017_bib99","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.ccell.2018.07.002","article-title":"Integrated genomic analysis of hurthle cell cancer reveals oncogenic drivers, recurrent mitochondrial mutations, and unique chromosomal landscapes","volume":"34","author":"Ganly","year":"2018","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.ecl.2025.03.017_bib100","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.ccell.2018.06.013","article-title":"Widespread chromosomal losses and mitochondrial DNA alterations as genetic drivers in hurthle cell carcinoma","volume":"34","author":"Gopal","year":"2018","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.ecl.2025.03.017_bib101","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/00000658-200003000-00005","article-title":"Insular and anaplastic carcinoma of the thyroid: a 45-year comparative study at a single institution and a review of the significance of p53 and p21","volume":"231","author":"Lam","year":"2000","journal-title":"Ann Surg"},{"issue":"1","key":"10.1016\/j.ecl.2025.03.017_bib102","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1001\/archotol.1988.01860130044012","article-title":"Anaplastic thyroid carcinoma. Association with differentiated thyroid cancer","volume":"114","author":"Spires","year":"1988","journal-title":"Arch Otolaryngol Head Neck Surg"},{"issue":"2","key":"10.1016\/j.ecl.2025.03.017_bib103","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/1097-0142(19900715)66:2<321::AID-CNCR2820660221>3.0.CO;2-A","article-title":"Anaplastic carcinoma of the thyroid. A clinicopathologic study of 121 cases","volume":"66","author":"Venkatesh","year":"1990","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.ecl.2025.03.017_bib104","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.113826","article-title":"The genomic and evolutionary landscapes of anaplastic thyroid carcinoma","volume":"43","author":"Zeng","year":"2024","journal-title":"Cell Rep"},{"issue":"2","key":"10.1016\/j.ecl.2025.03.017_bib105","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/his.14550","article-title":"Primary high-grade non-anaplastic thyroid carcinoma: a retrospective study of 364 cases","volume":"80","author":"Xu","year":"2022","journal-title":"Histopathology"},{"issue":"12","key":"10.1016\/j.ecl.2025.03.017_bib106","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1002\/gcc.22678","article-title":"Clonal evolution analysis of paired anaplastic and well-differentiated thyroid carcinomas reveals shared common ancestor","volume":"57","author":"Dong","year":"2018","journal-title":"Genes Chromosomes Cancer"},{"issue":"1","key":"10.1016\/j.ecl.2025.03.017_bib107","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1038\/s41467-019-10680-5","article-title":"Integrative analysis of genomic and transcriptomic characteristics associated with progression of aggressive thyroid cancer","volume":"10","author":"Yoo","year":"2019","journal-title":"Nat Commun"},{"issue":"11","key":"10.1016\/j.ecl.2025.03.017_bib108","doi-asserted-by":"crossref","DOI":"10.1172\/JCI169653","article-title":"Anaplastic transformation in thyroid cancer revealed by single-cell transcriptomics","volume":"133","author":"Lu","year":"2023","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1016\/j.ecl.2025.03.017_bib109","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41574-023-00920-6","article-title":"Genomic alterations in thyroid cancer: biological and clinical insights","volume":"20","author":"Landa","year":"2024","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.ecl.2025.03.017_bib110","series-title":"WHO classification of tumours series. Vol. 10","article-title":"Endocrine and neuroendocrine tumours [Internet]","author":"Board","year":"2022"},{"issue":"12","key":"10.1016\/j.ecl.2025.03.017_bib111","doi-asserted-by":"crossref","first-page":"4735","DOI":"10.1210\/jc.2009-1233","article-title":"RAS mutations are the predominant molecular alteration in poorly differentiated thyroid carcinomas and bear prognostic impact","volume":"94","author":"Volante","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.ecl.2025.03.017_bib112","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1002\/cncr.21739","article-title":"Poorly differentiated thyroid carcinomas defined on the basis of mitosis and necrosis: a clinicopathologic study of 58 patients","volume":"106","author":"Hiltzik","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.ecl.2025.03.017_bib113","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1038\/ncomms3185","article-title":"Frequency of TERT promoter mutations in human cancers","volume":"4","author":"Vinagre","year":"2013","journal-title":"Nat Commun"},{"issue":"9","key":"10.1016\/j.ecl.2025.03.017_bib114","doi-asserted-by":"crossref","first-page":"E1562","DOI":"10.1210\/jc.2013-2383","article-title":"Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease","volume":"98","author":"Landa","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.ecl.2025.03.017_bib115","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1530\/ERC-13-0210","article-title":"Highly prevalent TERT promoter mutations in aggressive thyroid cancers","volume":"20","author":"Liu","year":"2013","journal-title":"Endocr Relat Cancer"},{"issue":"6","key":"10.1016\/j.ecl.2025.03.017_bib116","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1530\/ERC-17-0562","article-title":"Interaction of BRAF-induced ETS factors with mutant TERT promoter in papillary thyroid cancer","volume":"26","author":"Song","year":"2019","journal-title":"Endocr Relat Cancer"},{"issue":"11","key":"10.1016\/j.ecl.2025.03.017_bib117","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1158\/1541-7786.MCR-23-0144","article-title":"Telomerase upregulation induces progression of mouse BrafV600E-driven thyroid cancers and triggers nontelomeric effects","volume":"21","author":"Landa","year":"2023","journal-title":"Mol Cancer Res"},{"issue":"35","key":"10.1016\/j.ecl.2025.03.017_bib118","doi-asserted-by":"crossref","first-page":"eadg7125","DOI":"10.1126\/sciadv.adg7125","article-title":"TERT accelerates BRAF mutant-induced thyroid cancer dedifferentiation and progression by regulating ribosome biogenesis","volume":"9","author":"Yu","year":"2023","journal-title":"Sci Adv"},{"issue":"13","key":"10.1016\/j.ecl.2025.03.017_bib119","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1158\/1078-0432.CCR-18-0373","article-title":"Genetic analysis of 779 advanced differentiated and anaplastic thyroid cancers","volume":"24","author":"Pozdeyev","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.ecl.2025.03.017_bib120","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1530\/ERC-19-0452","article-title":"Genetic profile of advanced thyroid cancers in relation to distant metastasis","volume":"27","author":"Song","year":"2020","journal-title":"Endocr Relat Cancer"},{"issue":"6","key":"10.1016\/j.ecl.2025.03.017_bib121","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1111\/his.13942","article-title":"Mutational profiling of poorly differentiated and anaplastic thyroid carcinoma by the use of targeted next-generation sequencing","volume":"75","author":"Duan","year":"2019","journal-title":"Histopathology"},{"issue":"5","key":"10.1016\/j.ecl.2025.03.017_bib122","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1089\/thy.2016.0254","article-title":"Molecular pathology of anaplastic thyroid carcinomas: a retrospective study of 144 cases","volume":"27","author":"Bonhomme","year":"2017","journal-title":"Thyroid"},{"issue":"6","key":"10.1016\/j.ecl.2025.03.017_bib123","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1002\/hed.25634","article-title":"Unique mutation patterns in anaplastic thyroid cancer identified by comprehensive genomic profiling","volume":"41","author":"Khan","year":"2019","journal-title":"Head Neck"},{"issue":"8","key":"10.1016\/j.ecl.2025.03.017_bib124","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1093\/hmg\/ddu749","article-title":"Characterization of the mutational landscape of anaplastic thyroid cancer via whole-exome sequencing","volume":"24","author":"Kunstman","year":"2015","journal-title":"Hum Mol Genet"},{"issue":"7","key":"10.1016\/j.ecl.2025.03.017_bib125","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41571-020-0357-3","article-title":"The SWI\/SNF complex in cancer - biology, biomarkers and therapy","volume":"17","author":"Mittal","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"10.1016\/j.ecl.2025.03.017_bib126","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/cr.2011.32","article-title":"ATP-dependent chromatin remodeling: genetics, genomics and mechanisms","volume":"21","author":"Hargreaves","year":"2011","journal-title":"Cell Res"},{"issue":"5","key":"10.1016\/j.ecl.2025.03.017_bib127","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1158\/2159-8290.CD-20-0735","article-title":"SWI\/SNF complex mutations promote thyroid tumor progression and insensitivity to redifferentiation therapies","volume":"11","author":"Saqcena","year":"2021","journal-title":"Cancer Discov"},{"issue":"9","key":"10.1016\/j.ecl.2025.03.017_bib128","first-page":"1039","article-title":"The 2023 Bethesda system for reporting thyroid cytopathology","volume":"33","author":"Ali","year":"2023","journal-title":"Thyroid"},{"issue":"3","key":"10.1016\/j.ecl.2025.03.017_bib129","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1097\/SLA.0000000000003580","article-title":"The American association of endocrine surgeons guidelines for the definitive surgical management of thyroid disease in adults","volume":"271","author":"Patel","year":"2020","journal-title":"Ann Surg"},{"issue":"5","key":"10.1016\/j.ecl.2025.03.017_bib130","first-page":"231","article-title":"Molecular testing for indeterminate thyroid nodules: past, present, and future","volume":"30","author":"Raghunathan","year":"2023","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"8","key":"10.1016\/j.ecl.2025.03.017_bib131","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1002\/cncr.31245","article-title":"Analytical performance of the ThyroSeq v3 genomic classifier for cancer diagnosis in thyroid nodules","volume":"124","author":"Nikiforova","year":"2018","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.ecl.2025.03.017_bib132","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1001\/jamaoncol.2020.5935","article-title":"Effectiveness of molecular testing techniques for diagnosis of indeterminate thyroid nodules: a randomized clinical trial","volume":"7","author":"Livhits","year":"2021","journal-title":"JAMA Oncol"},{"issue":"7","key":"10.1016\/j.ecl.2025.03.017_bib133","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1210\/jc.2015-1158","article-title":"Molecular testing for miRNA, mRNA, and DNA on fine-needle aspiration improves the preoperative diagnosis of thyroid nodules with indeterminate cytology","volume":"100","author":"Labourier","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"10.1016\/j.ecl.2025.03.017_bib134","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/cncy.22829","article-title":"The role of the ThyGeNEXT oncogene panel used in combination with the expanded miRNA panel ThyraMIRv2 in Indeterminate thyroid nodules: a large, blinded, real-world, observational study","volume":"132","author":"Verma","year":"2024","journal-title":"Cancer Cytopathol"},{"issue":"12","key":"10.1016\/j.ecl.2025.03.017_bib135","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1002\/dc.24564","article-title":"Multiplatform molecular test performance in indeterminate thyroid nodules","volume":"48","author":"Lupo","year":"2020","journal-title":"Diagn Cytopathol"},{"key":"10.1016\/j.ecl.2025.03.017_bib136","article-title":"Evaluating the clinical performance of an updated microRNA classifier in indeterminate and RAS-mutated thyroid nodule management: a multi-institutional study","volume":"177","author":"Tumati","year":"2024","journal-title":"Surgery"}],"container-title":["Endocrinology and Metabolism Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852925000398?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852925000398?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T23:03:40Z","timestamp":1753484620000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889852925000398"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":136,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S0889852925000398"],"URL":"https:\/\/doi.org\/10.1016\/j.ecl.2025.03.017","relation":{},"ISSN":["0889-8529"],"issn-type":[{"value":"0889-8529","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Update on Somatic Genomic Alterations in Follicular Cell-Derived Thyroid Cancers","name":"articletitle","label":"Article Title"},{"value":"Endocrinology and Metabolism Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ecl.2025.03.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}